KR102037897B1 - Composition for Preventing or Treating Obesity Comprising Lactic Acid Bacteria from Kefir and Grape Seed Flour - Google Patents

Abstract

The present invention relates to a composition for the prevention or treatment of obesity, including grape seed powder and kefir-derived lactic acid bacteria. The composition comprising kefir-derived lactic acid bacteria and grape seed powder according to the present invention, grape seed powder acts as a prebiotic and lactic acid bacteria complex cells isolated from kefir act as probiotics to prevent weight gain due to high fat diet, total It lowers cholesterol levels and has the effect of insulin resistance, which can be utilized as a functional food or pharmaceutical composition for the prevention or treatment of obesity.

Description

Composition for Preventing or Treating Obesity Comprising Lactic Acid Bacteria from Kefir and Grape Seed Flour}

The present invention relates to functional foods and pharmaceutical compositions for improving, preventing or treating obesity, including kefir-derived lactic acid bacteria and grape seed powder.

Obesity, which is a disorder of geological metabolism, is often accompanied by metabolic disorders, and its population is increasing worldwide. Recently, the obese population has surpassed the low nutritional and infectious diseases population. The causes of obesity can range from endocrine, genetic and environmental factors.

Kefir is a type of fermented milk derived from the Caucasus mountainous region and popularized by Tibetan monks for health. Kefir's nutrients include proteins and polysaccharides, and include vitamin A, vitamin B1, vitamin B2, vitamin B6, vitamin D, vitamin K2, folic acid, nicotinic acid, calcium, iron, and iodine. Such kefir is a yoghurt-like beverage obtained by fermenting milk using a strain (also referred to as kefir granules) called lactic acid bacteria and kefir grains as a yeast complex as an initiator.

Kefir, a beverage fermented by kefir grains, contains lactic acid bacteria that are beneficial to the human body, which is known to be effective in inhibiting constipation, improving gastrointestinal disorders by promoting intestinal activity, and enhancing the immune system. For example, Korean Unexamined Patent Publication No. 10-2017-0115820 provides a composition for preventing or treating food poisoning comprising kefir as an active ingredient, and Korean Patent Publication No. 10-1426399 discloses kefir for improving constipation And it provides a manufacturing method thereof. However, the effects of kefir on the prevention or treatment of metabolic disorders other than intestinal health are not well understood.

Probiotics are gut flora that is good for health, ie living microorganisms, or live fungi, that benefit the health of the host. Probiotics are generally consumed as part of fermented foods such as yoghurt or as a dietary supplement. Microorganisms known as probiotics include lactic acid bacteria, bifidobacteria, and Bacillus.

Similar to probiotics, prebiotics are indigestible ingredients that help the growth of beneficial organisms in the gut, and are substances that help improve the intestinal environment by becoming a source of probiotics. In order for any food ingredient to be used by a useful microorganism in the large intestine to be used as a prebiotics that promotes the growth or activity of the microorganism and thus has a beneficial effect on host health, it must not be digested or absorbed from the upper part of the gastrointestinal tract, It should be able to selectively activate the medium useful bacteria and suppress harmful bacteria such as pathogens.

On the other hand, grapes contain a lot of polyphenol-based resveratrol, an antioxidant found in plants, and resveratrol is a powerful antioxidant that has antibacterial, anticancer, antiviral, antiallergic, and anti-inflammatory effects. As a substance that has an active function, it contains a large amount of grape by-products such as peel, seed, and pine branches, so if you discard the grape by-products, you will not only lose useful components contained in the agricultural products, but also by-products of environmental pollution. Increasing the utility value of research is being actively conducted.

The present inventors completed the present invention by confirming that kefir-derived lactic acid bacteria and grape seed powder act as probiotics and prebiotics, respectively, and are effective for the prevention or treatment of obesity.

An object of the present invention for solving such a problem is to provide a food for improving obesity, including kefir-derived lactic acid bacteria and grape seed powder.

Another object of the present invention to provide a pharmaceutical composition for the prevention or treatment of obesity, including kefir-derived lactic acid bacteria and grape seed powder.

In order to achieve the above object, the present invention provides a functional food for improving obesity comprising kefir-derived lactic acid bacteria and grape seed powder as an active ingredient.

In the present invention, the kefir-derived lactic acid bacterium may be Leuconostoc mesenteroides, Lactobacillus kefiri, or a combination thereof, and preferably, Lyukconstock mesenteroides LCM4 ( leuconostoc mesenteroides LCM4, Accession No .: KCCM12117P) and Lactobacillus kefiri DH5 (Accession No .: KCCM11837P).

In the present invention, the complex cells may include leukonostock mesenteroides LCM4 and Lactobacillus kepyri DH5 in a concentration ratio of 1: 5 to 1:20.

In the present invention, the kefir-derived lactic acid bacteria may be included in an amount of 0.1 to 10% by weight based on the mass of the grape seed powder.

In the present invention, the grape seed powder may be a byproduct of wine production, and may be made of grapes of Chardonnay varieties.

The functional food of the present invention can improve obesity by increasing intestinal short-chain fatty acids.

In the present invention, the functional food may be fermented food.

The present invention also provides a pharmaceutical composition for the prevention or treatment of obesity, including kefir-derived lactic acid bacteria and grape seed powder as an active ingredient.

The composition comprising kefir-derived lactic acid bacteria and grape seed powder according to the present invention, grape seed powder acts as a prebiotic and lactic acid bacteria complex cells isolated from kefir act as probiotics to prevent weight gain due to high fat diet, total It lowers cholesterol levels and has the effect of insulin resistance, which can be utilized as a functional food or pharmaceutical composition for the prevention or treatment of obesity.

Figure 1 is a graph showing the weight change of the mice ingested the diet of the Examples and Comparative Examples of the present invention.
Figure 2 shows the fat cell images of the mice ingested the diet of the Examples and Comparative Examples of the present invention.
Figure 3 shows a list of representative genes expressed at a rate of 1.8 times or more for the mice that did not take the grape seed powder in the epididymal adipose tissue of the mice fed the grape seed powder.
Figure 4 shows a list of representative genes expressed more than 8 times in the epididymal adipose tissue of mice fed Kefir-derived Lactobacillus complex cells, but not in mice fed Kefir-derived Lactobacillus complex cells.
Figure 5 shows a list of genes expressed at a rate of 1.8 times or more for the mice that did not ingest the epididymal adipose tissue of mice fed grape seed powder and kefir-derived lactic acid bacteria complex cells.
Figure 6 shows the results of ingenuity pathway analysis (IPA) analysis of the adipose tissue of mice fed grape seed powder.
Figure 7 shows the results of IPA analysis of the adipose tissue of the mice ingested kefir-derived lactic acid bacteria.
Figure 8 shows the results of IPA analysis of the adipose tissue of the mice ingested grape seed powder and kefir-derived lactic acid bacteria.
Figure 9 shows the synthesis of the genetic changes of the mice ingested grape seed powder.
10 shows a summary of the genetic changes of the mice ingested kefir-derived lactic acid bacteria.
Figure 11 shows the synthesis of the genetic changes of the mice ingested grape seed powder and kefir-derived lactic acid bacteria.

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. In general, the nomenclature used herein is well known and commonly used in the art.

The present invention relates to a composition for improving obesity containing kefir-derived lactic acid bacteria and grape seed powder as an active ingredient.

In the present invention, "probiotics" means a strain that has a beneficial effect on the intestinal environment when ingested and reaches the intestine.

In the present invention, "Prebiotics" is an indigestible ingredient that helps the growth of beneficial bacteria in the intestine, and refers to a substance that helps to improve the intestinal environment by becoming a nutrient source of probiotics.

In the present invention, kefir (kefir) is a kind of fermented milk derived from Caucasus mountainous fat, kefir refers to a yogurt-like beverage obtained by fermenting milk with an initiator of a species called lactic acid bacteria and kefir grains, a yeast complex. .

Kefir-derived lactic acid bacteria that can be used in the present invention may be leuconostoc mesenteroides , Lactobacillus kefiri , or complex cells thereof.

Preferably, the kefir-derived lactic acid bacterium usable in the present invention may be leuconostoc LCM4 ( leuconostoc). mesenteroides LCM4, Depositary: Korea Center for Conservation of Microorganisms, Accession No .: KCCM12117P, Date of Deposit: September 21, 2017), Lactobacillus kefiri DH5, Depositary Organization: Korea Microorganism Conservation Center, Accession No .: KCCM11837P, Accession Date: April 29, 2016), or complex cells thereof. Most preferably, the use of a complex cell of leukonostock mesenteroides LCM4 and Lactobacillus kepyri DH5 is suitable for the prevention or treatment of obesity. The complex cells may be used by mixing the leukonostock mesenteroides LCM4 and Lactobacillus kepyri DH5 in a concentration of 1: 1 to 1: 100, preferably used in a concentration of 1: 5 to 1:20. Can be.

The inventors have confirmed that grape seed powder acts as a prebiotics which has a beneficial effect on the probiotic activity of kefir-derived lactic acid bacteria.

There is no particular limitation on the variety, production region or harvesting time of the grapes used in the present invention. Chardonnay grapes are most preferably used.

The grape seed powder of the present invention may be produced from by-products generated during the manufacture of beverages or liquors based on grapes. Preferably, the grape seed powder may be produced from by-products generated during the production of wine or wine.

Here, "by-product" is a generic term for the remaining products other than wine or wine distillate produced in the distillation process after the crushing and fermentation process using grape as a raw material.

Typically, by-products of wine or wine making are discarded. However, these wastes account for 40% of the raw grapes, which is a significant economic loss. According to the present invention, since by-products generated during wine production can be utilized as prebiotics, there is a great environmental and economic advantages.

According to one embodiment of the present invention, "Grape seed flour" (Grape seed flour, GSF) is produced by separating the grape seed from the by-products remaining from the wine, dried, and then from the grape seed using the "cool press", "heat press" technique, etc. It can be produced by extracting the oil and then grinding it into powder. Separation, drying, compacting and grinding methods of the grape seed powder may be carried out in various forms by conventionally known techniques.

The particle size of the grape seed powder can be varied according to the grinding environment, and an additional sifting operation can be added to produce a powder with smaller particles. The particle size of the grape seed powder can be adjusted to suit the intended use and purpose of food and medicine.

In the present invention, when the grape seed powder and kefir-derived lactic acid bacteria were found to have an excellent effect on improving obesity due to high fat diet. In particular, it was confirmed that the grape seed powder and the kefir-derived lactic acid bacteria exhibited synergistic effects when ingested together and showed remarkable effects that were difficult to predict from the ingestion of each of them.

Specifically, when ingested together with grape seed powder and kefir-derived lactic acid bacteria can suppress weight gain due to high fat diet. In one embodiment of the present invention, when the high-fat diet-induced obese mice were ingested with grape seed powder and kefir-derived lactic acid for 9 weeks with a high-fat diet, it was confirmed that the weight is reduced, and thus the composition of the present invention is obese It was confirmed that it can exert an excellent effect on prevention or treatment.

The rats ingested grape seed powder and kefir-derived lactic acid bacteria of the present invention actually confirmed that the size of adipose tissue was significantly reduced, and it was confirmed that the total cholesterol and insulin levels could be greatly reduced. Insulin is a hormone that induces differentiation of fat cells and is a major external factor involved in the regulation of fat cell metabolism.

In addition, the grape seed powder and kefir-derived lactic acid bacteria of the present invention are absorbed into the body to increase short chain fatty acids such as acetic acid or propionic acid. Short-chain fatty acids are known to be effective in anti-obesity and anti-inflammatory.

The kefir-derived lactic acid bacteria is preferably used in an amount of 0.1 to 10% by weight, and more preferably 0.5 to 5% by weight, based on the mass of the grape seed powder.

The composition containing the grape seed powder and kefir derived lactic acid bacteria of the present invention can be utilized as a functional food.

The functional food is preferably a fermented food, but is not limited thereto. For example, the functional food may be beverages, gums, teas, vitamin complexes, dietary supplements, and more specifically, dairy products, confectionery, condiments, beverages and drinks, snacks, candies, jelly, ice cream and frozen desserts. , Breakfast cereals, nutrition bars, snack bars chocolate products, processed foods, grain products and pastas, soups, sauces and dressings, confectionery products, oils and fats products, dairy drinks and milk drinks, tea, soy milk and soy milk products (soy dairy-like product), frozen foods, cooked foods and substitutes, meat products, cheese, yogurt, bread and buns, cakes, cookies and crackers.

In addition, the functional food may be prepared in the form of capsules, tablets, powders, liquid suspensions, pills and granules, including kefir-derived lactic acid bacteria and grape seed powder.

In addition, the functional food may further include components normally added during food production, as well as kefir-derived lactic acid bacteria and grape seed powder as an active ingredient.

Functional foods of the present invention include various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic and natural flavors, coloring and neutralizing agents (such as cheese, chocolate), pectic acid and salts thereof, alginic acid and salts thereof , Organic acids, protective colloid thickeners, pH regulators, stabilizers, preservatives, glycerin, alcohol, carbonation agent used in carbonated drinks, and the like, and may contain fruit juice or pulp for preparing vegetable drinks.

The composition containing the grape seed powder and kefir-derived lactic acid bacteria of the present invention can also be utilized as a pharmaceutical composition for the prevention or treatment of obesity.

The pharmaceutical composition according to the present invention contains kefir-derived lactic acid bacteria and grape seed powder as active ingredients, and may further include a suitable carrier, excipient or diluent according to a conventional method. The pharmaceutically acceptable carrier is conventionally used in the preparation, lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia rubber, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, Polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil, and the like.

The pharmaceutical composition of the present invention may further include lubricants, wetting agents, sweeteners, flavoring agents, emulsifiers, suspending agents, preservatives, etc. in addition to the above components. Suitable pharmaceutically acceptable carriers and formulations may be preferably formulated according to each component using the methods disclosed in Remington's Pharmaceutical Sciences (19th ed., 1995).

The pharmaceutical composition of the present invention can be oral or parenteral administration, and parenteral administration includes intravenous injection, subcutaneous injection, intramuscular injection, intraperitoneal injection, transdermal administration and the like.

Formulations for oral administration include, for example, tablets, pills, hard capsules, soft capsules, solutions, suspensions, emulsifiers, syrups, granules, etc. These formulations may contain diluents (e.g., lactose, dextrose, water, etc.) in addition to the active ingredients. Cross, mannitol, sorbitol, cellulose and / or glycine), lubricants such as silica, talc, stearic acid and its magnesium or calcium salts and / or polyethylene glycols. The tablets may also contain binders such as magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and / or polyvinylpyrrolidine, optionally starch, agar, alginic acid. Or disintegrant or boiling mixtures such as sodium salts thereof and / or absorbents, colorants, flavors and sweeteners. The formulations may be prepared by conventional mixing, granulating or coating methods.

Representative formulations for parenteral administration are also injectable preparations, which include water, Ringer's solution, isotonic physiological saline or suspension as solvents for injectable preparations. Sterile fixed oils of the injectable preparations may be used as solvents or suspending media and any non-irritating fixed oil may be used for this purpose, including mono- and di-glycerides. In addition, the injectable preparation may use a fatty acid such as oleic acid.

The composition according to the invention is administered in a pharmaceutically effective amount. In the present invention, “pharmaceutically effective amount” means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment, and an effective dose level refers to the type, severity, and activity of the patient's disease. , Sensitivity to the drug, time of administration, route of administration and rate of release, duration of treatment, factors including concurrent use of the drug, and other factors well known in the medical arts. The composition according to the present invention may be administered as a separate therapeutic agent or in combination with other therapeutic agents, may be administered sequentially or simultaneously with conventional therapeutic agents, and may be single or multiple doses. Taking all of the above factors into consideration, it is important to administer an amount that can achieve the maximum effect with a minimum amount without side effects, which can be easily determined by those skilled in the art.

Specifically, the effective amount of the composition according to the present invention may vary depending on the age, sex and weight of the patient, and generally 0.001 to 150 mg, preferably 0.01 to 100 mg per 1 kg of body weight is administered daily or every other day or 1 to 1 day. It can be divided into three doses. However, the dosage may be increased or decreased depending on the route of administration, sex, weight, age, etc., and the above dosage does not limit the scope of the present invention in any way.

Example

Hereinafter, the present invention will be described in more detail with reference to Examples. These examples are only to illustrate the invention, it will be apparent to those of ordinary skill in the art that the scope of the present invention is not to be construed as limited by these examples.

Experiment preparation

Metabolic obesity Disease  Rat Preparation

Metabolic obesity disorders were induced in 86 C57BL / 6J mice by ingesting a high-fat diet "western diet" for 5 weeks.

Specific components of the high-fat diet to be used in the feed and the experimental examples below are shown in Table 1 below.

Ingredient (g / kg) High-fat diet Grape seed powder
Containing diet Lard fat 225.0 225.0 Soybean oil 21.1 13.5 Cholesterol 0.8 0.8 MCC
(Microcrystalline cellulose) 57.3 0 Casein 199.2 191.0 Corn starch 145.6 118.7 Sucrose 300.0 300.0 L Cystein 3.0 3.0 Choline bitartrate 3.0 3.0 Mineral mix 35.0 35.0 Vitamin Mix 93G 10.0 10.0 GSF 0 100.0 Total Diet weight 1000.0 1000.0

Kefir  Lactic Acid Bacteria Preparation

Lactobacillus leukonostock mesenteroides LCM4 and Lactobacillus kepyri DH5 isolated from kefir were cultured in MRS medium, and then powdered and mass-produced.

In MRS solid medium, leuconosstock mesenteroides LCM4 was incubated at 1 x 10 ¹⁰ CFU / mg, and Lactobacillus kepyri DH5 at 1 x 10 ⁹ CFU / mg, respectively, and the cultivated bacteria were collected by sterile physiological saline solution. The flask was placed in a flask on a stirrer and adjusted to turbidity 3.9 for LCM4 bacteria and 2.0 for DH5 bacteria.

Thereafter, centrifugation was performed at 4 ° C. and 3,000 rpm for 10 minutes. The supernatant was discarded, sterile saline was added and lyophilized to powder.

The powdered kefir-derived lactic acid bacteria were rehydrated at room temperature in 6 mL of sterile distilled water for about 1 hour before administration, and the samples of the two strains were mixed well in a ratio of 1: 1 and finally administered through tube administration (gavage). The mice were administered.

Grape Seed Powder Preparation

Chardonnay grape seed powder was purchased from ApresVin Enterprises, Inc., USA.

The grape seed powder is made by using Chardonnay grapes and cold-pressed the remaining by-products (cold-pressed), to remove the oil from the grape seed, hot air drying the remaining product, remove the skin portion using air blow Next, the remaining product is in the form of a fine seed grape seed powder (GSF) filtered using a sieve having a size of 100 mesh (150 microns).

Experimental Example  1: weight gain analysis

Sixty mice with metabolic obesity disease were divided into four groups to provide the diet of Table 2 for 9 weeks each. In Table 1 below, each value means the weight administered once based on 30g of mice.

Comparative Example 1 Comparative Example 2 Comparative Example 3 Example 1 High-fat diet
(Grape seed powder content,%) 4 g
(-) 4 g
10 4 g
(-) 4 g
10 Kefir-derived lactic acid bacteria
Complex cells - - 300 μg 300 μg

The weight change before and after ingesting the diet for 9 weeks is shown in FIG. 1.

In Figure 1, the rat of Comparative Example 1 ingested only high fat diet was observed weight gain of about 13.5g for 9 weeks.

The rats of Comparative Example 2 ingesting grape seed powder with high fat diet showed little change in weight, and the rats of Comparative Example 3 incorporating Kefir-derived lactic acid bacteria complex body weight gained about 7.5g for 9 weeks. .

On the other hand, the rats of Example 1 ingested grape seed powder and kefir-derived lactic acid bacteria combined with a high-fat diet, the weight of the body rather reduced by about 1g.

That is, it can be confirmed that the grape seed powder and the kefir-derived lactic acid bacteria complex act as synergistic effects with each other, and when they are ingested, they show a remarkable effect that is difficult to predict.

Experimental Example  2: fat cell size analysis

Experimental rats ingesting the diet of Example and Comparative Example for 9 weeks in Experimental Example 1 were extracted with epididymal adipose tissue and fixed in 10% formalin, and then hematoxylin-eosin double staining (H & E stain) was performed. The results are shown in FIG.

In Figure 2, it can be seen that the cell size of the mice ingesting the diet of Example 1 is the smallest compared to any of Comparative Examples 1 to 3. This suggests that ingestion of grape seed powder and kefir-derived lactic acid bacteria complexes together may provide the best anti-obesity effect.

Experimental Example  3: biochemical test

Table 3 shows the results of the following items from the blood of the rats fed the diet of Example and Comparative Example for 9 weeks in Experimental Example 1 using a biochemical automatic analyzer (7020, HITACHI).

Inspection items:

Triglyceride (TG, mg / dL)

Total cholesterol (T.C, mg / dL)

Glucose (mg / dL),

Insulin (ng / mL)

Comparative Example 1 Comparative Example 2 Comparative Example 3 Example 1 TG
(mg / dL) 51.2 ± 5.1 30 ± 3.6 37.1 ± 3.6 31.2 ± 2.2 TC
(mg / dL) 266.1 ± 23.4 174.2 ± 18.3 233.1 ± 15.7 161.2 ± 10.1 Glucose (mg / dL) 172.1 ± 6.2 134.2 ± 5.3 156.6 ± 10.1 135.9 ± 5.7 Insulin (ng / mL) 2.7 ± 0.3 1.0 ± 0.1 1.1 ± 0.3 0.8 ± 0.1

In Table 3, no special synergistic effect was observed for TG and glucose, but the rats of Example 1 in which grape seed powder and kefir-derived lactic acid complex cells were ingested in TC and insulin levels were compared with each of them. It can be seen that it represents a significantly lower value than the average value of the mouse of Example 2 or 3.

Experimental Example  4: Short-chain fatty acid  Measure

In the experimental example 1, the cecum extracted from the rats ingesting the diets of the Examples and Comparative Examples for 9 weeks was filled with eluent dissolved in Na ₂ CO ₃ in 3.6 mM in demineralized water to 1.5 mL, and then sonicated for 1 hour. It was ground and eluted. The eluted sample was centrifuged to obtain a supernatant. The supernatant was filtered with a syringe filter, diluted 100-fold with the eluent, and analyzed by IC. The results are shown in Table 4 below.

Comparative Example 1 Comparative Example 2 Comparative Example 3 Example 1 Acetic acid (mg / L) 52.5 ± 20.7 84.1 ± 16.5 7.1 ± 6.5 100.5 ± 41.4 Propionic acid (mg / L) 9.8 ± 4.9 28.3 ± 7.9 15.8 ± 11.9 49.9 ± 8.0

In Table 4, the mice of Example 1, which were ingested together with grape seed powder and kefir-derived lactic acid bacteria complex cells, had higher amounts of short-chain fatty acids (acetic acid and propionic acid) than the simple summation of the mice of Comparative Example 2 or 3, respectively. ).

Experimental Example  5: in the epididymal adipose tissue microarray  Gene profiling by analysis

After RNA was isolated from the epididymal tissue of the rats fed the diet of Example and Comparative Example for 9 weeks in Experimental Example 1, microarray analysis was performed using an Agilent microarray chip.

Comparison of the control group (Comparative Example 1) and Example 1, and Comparative Examples 1 and 2 are listed in Figures 3 to 5 statistically significant and large change. In addition, significant pathways are shown in FIGS. 6 to 8 through Ingenuity pathway analysis (IPA), respectively.

The results of the microarray analysis and the IPA analysis are shown in FIGS. 9 to 11.

In Fig. 9, mice fed grape seed powder were specifically related to angiogenesis, response to LPS, lipoichoic acid, and peptidoglycan compared to the control group. We can see that the genes are greatly reduced.

In Figure 10, the mice ingested kefir-derived lactic acid bacteria specifically diet-induced thermogenesis, WNT inhibition of Wnts, ceramide synthesis and defensin compared to the control group The genes involved in defensin are significantly affected.

Finally, in FIG. 11, mice ingested with grape seed powder and kefir-derived lactic acid bacteria specifically reduced genes related to the NLRP inflammasone complex assembly compared to the control group.

That is, when ingesting a composition containing grape seed powder and kefir-derived lactic acid bacteria, it was confirmed that due to the change of these genes, it plays an important role in improving obesity, insulin resistance, inflammation, oxidative stress, etc. by the high-fat diet.

As described above in detail a specific part of the content of the present invention, for those of ordinary skill in the art, such a specific description is only a preferred embodiment, which is not limited by the scope of the present invention Will be obvious. Thus, the substantial scope of the present invention will be defined by the appended claims and their equivalents.

Claims (10)

Kefir derived lactic acid bacteria and grape seed powder as an active ingredient,
The kefir-derived lactic acid bacteria contained leuconostoc mesenteroides LCM4 ( leucoostoc mesenteroides LCM4, Accession No .: KCCM12117P) and Lactobacillus kepyri DH5 ( Lactobacillus kefiri DH5, Accession No .: KCCM11837P) at a concentration ratio of 1: 5 to 1:20. Functional food for improving obesity, characterized in that the complex cells containing.
delete delete delete The method of claim 1,
Functional food for improving obesity, characterized in that the grape seed powder is a wine production by-product.
The method of claim 1,
The grape seed powder is characterized in that the chardonnay (Chardonnay) varieties, characterized in that the functional food for improving obesity.
The method of claim 1,
The kefir-derived lactic acid bacteria, characterized in that contained in 0.1 to 10% by weight based on the mass of the grape seed powder, functional food for improving obesity.
The method of claim 1,
Functional food for improving obesity, characterized by increasing the intestinal short-chain fatty acid.
The method of claim 1,
Functional food for improving obesity, characterized in that the functional food is a fermented food.
Kefir-derived lactic acid bacteria and grape seed powder as an active ingredient,
The kefir-derived lactic acid bacteria contained leuconostoc mesenteroides LCM4 ( leucoostoc mesenteroides LCM4, Accession No .: KCCM12117P) and Lactobacillus kepyri DH5 ( Lactobacillus kefiri DH5, Accession No .: KCCM11837P) at a concentration ratio of 1: 5 to 1:20. A pharmaceutical composition for preventing or treating obesity, characterized in that the complex cells comprising.

Images